Modra Pharmaceuticals Starts Phase 2 Trial of Oral Docetaxel in Metastatic Prostate Cancer

Modra Pharmaceuticals Starts Phase 2 Trial of Oral Docetaxel in Metastatic Prostate Cancer
Modra Pharmaceuticals has enrolled its first patient in a Phase 2 clinical trial (NCT03136640) of  ModraDoc006/r as a treatment for metastatic castration-resistant prostate cancer — an advanced and often fatal form of the disease ModraDoc006/r is a tablet formulation of docetaxel. Doctors administer it with the chemotherapy ritonavir to boost ritonavir's bioavailablity, or amount that the body can absorb. “Modra Pharmaceuticals aims to apply its oral formulation technology in oncology [cancer treatment], with an initial focus on taxane-based chemotherapy, to offer patients a better quality of life through a simpler and m
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *